0000899243-20-032454.txt : 20201202
0000899243-20-032454.hdr.sgml : 20201202
20201202094612
ACCESSION NUMBER: 0000899243-20-032454
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201202
FILED AS OF DATE: 20201202
DATE AS OF CHANGE: 20201202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wegman Mark N
CENTRAL INDEX KEY: 0001405235
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34236
FILM NUMBER: 201362584
MAIL ADDRESS:
STREET 1: 43 OVERLOOK ROAD
CITY: OSSINING
STATE: NY
ZIP: 10562
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP
CENTRAL INDEX KEY: 0000875622
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 113054851
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 WILBUR ST
CITY: LYNBROOK
STATE: NY
ZIP: 11563
BUSINESS PHONE: 302-842-8450
MAIL ADDRESS:
STREET 1: 2 RIGHTER PARKWAY, SUITE 200
CITY: WILMINGTON
STATE: DE
ZIP: 19803
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-02
1
0000875622
BIOSPECIFICS TECHNOLOGIES CORP
BSTC
0001405235
Wegman Mark N
C/O BIOSPECIFICS TECHNOLOGIES CORP.
2 RIGHTER PKWY, DE CORP CENTER II
WILMINGTON
DE
19803
1
0
1
0
Common Stock, $0.001 par value
2020-11-17
4
G
0
2400
0.00
D
66488
D
Common Stock, $0.001 par value
2020-12-02
4
D
0
64762
D
1726
D
Common Stock, $0.001 par value
2020-12-02
4
D
0
1726
D
0
D
Common Stock, $0.001 par value
2020-12-02
4
D
0
935073
D
0
I
See footnote
On November 17, 2020, the reporting person transferred 2,400 shares of common stock to a charitable fund.
Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020 (the "Merger Agreement"), 64,762 shares of common stock were exchanged for a cash payment of $5,731,437, representing the product obtained by multiplying the offer price ($88.50) by the number of shares owned by the reporting person.
Upon the consummation of the Merger, pursuant to the Merger Agreement, 1,726 outstanding restricted stock units ("RSUs") were cancelled in exchange for a cash payment of $152,751.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the RSUs, by (y) the offer price ($88.50).
Upon the consummation of the Merger, 935,073 shares of common stock held by the MARITAL TRUST U/W/O EDWIN H WEGMAN DATED 08/10/06 (the "Trust") were exchanged for a cash payment of $82,753,960.50, representing the product obtained by multiplying the offer price ($88.50) by the number of shares owned by the Trust.
These shares are held in trust on behalf of the reporting person. The reporting person is the co-trustee of the Trust. The reporting person disclaims beneficial ownership of the shares held by the Trust except to the extent of the reporting person's pecuniary interest therein.
Mark N. Wegman, by Carl A. Valenstein, attorney-in-fact
2020-12-02